Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
27.05
-0.17 (-0.62%)
At close: Feb 9, 2026, 4:00 PM EST
27.01
-0.04 (-0.15%)
After-hours: Feb 9, 2026, 7:59 PM EST
Pfizer Revenue
In the year 2025, Pfizer had annual revenue of $62.58B, down -1.65%. Pfizer had revenue of $17.56B in the quarter ending December 31, 2025, a decrease of -1.16%.
Revenue (ttm)
$62.58B
Revenue Growth
-1.65%
P/S Ratio
2.46
Revenue / Employee
$772,580
Employees
81,000
Market Cap
153.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.58B | -1.05B | -1.65% |
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | 15.90B | 32.26% |
| Dec 31, 2009 | 49.27B | 973.00M | 2.01% |
| Dec 31, 2008 | 48.30B | -122.00M | -0.25% |
| Dec 31, 2007 | 48.42B | 47.00M | 0.10% |
| Dec 31, 2006 | 48.37B | 966.00M | 2.04% |
| Dec 31, 2005 | 47.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| AbbVie | 61.16B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
PFE News
- 1 day ago - Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity - Seeking Alpha
- 3 days ago - Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data - CNBC
- 3 days ago - 14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS) - Seeking Alpha
- 3 days ago - FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need - Business Wire
- 4 days ago - Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans - Business Wire
- 6 days ago - Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Pfizer: Messy Q4 Earnings Mask An Improving Business - Seeking Alpha
- 6 days ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters